WAT — Waters Corporation stock price, charts and financials

QT61Waters Corporation

Waters Corporation (NYSE: WAT) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
411.12
+4.25+1.05%
WATQT61Waters Corporation·NYSE
411.12+1.05%
News
Up 1.0% — Waters Q2 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E101.21EPS (ttm)4.02Insider Own0.76%Shs Outstand74.79MPerf Week7.83%
Market Cap30.43BForward P/E24.62EPS next Y16.52Insider Trans-0.43%Shs Float74.70MPerf Month7.88%
Enterprise Value34.98BPEG-EPS next Q-Inst Own-Short Float4.90%Perf Quarter16.08%
Income126.53BP/S6.55EPS this Y85.13%Inst Trans-Short Ratio3.63Perf Half Y7.95%
Sales4.64BP/B0.00EPS next Y13.41%ROA0.67%Short Interest3.66MPerf YTD7.12%
Book/sh-P/C0.07EPS next 5Y11.09%ROE1.88%52W High418.48 -1.76%Perf Year46.50%
Cash/sh-P/FCF76.75EPS past 3/5Y-2.84% 5.18%ROIC1.28%52W Low277.93 47.92%Perf 3Y39.45%
Dividend Est.-EV/EBITDA39.05Sales past 3/5Y2.12% 6.00%Gross Margin50.78%Volatility3.33% 3.22%Perf 5Y4.37%
Dividend TTM-EV/Sales7.53EPS Y/Y TTM-26.52%Oper. Margin7.96%ATR (14)12.90Perf 10Y159.05%
Dividend Ex-DateNov 26, 1996Quick Ratio0.00Sales Y/Y TTM27.45%Profit Margin3.58%RSI (14)67.43Recom2.61
Dividend Gr. 3/5Y-Current Ratio0.00EPS Q/Q20.00%SMA207.15%Beta1.18Target Price420.64
Payout0.00%Debt/Eq0.33Sales Q/Q91.39%SMA508.95%Rel Volume0.85Prev Close406.86
Employees7,900LT Debt/Eq0.39EarningsNov 03SMA20014.32%Avg Volume967.86KPrice411.12
IPO DateNov 17, 1995Option/ShortYes / YesEPS/Sales Surpr.17.04% 5.30%Net Debt/EBITDA5.08Volume818,170Change1.05%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedMorgan StanleyEqual Weight$390$430
Aug-05-26ReiteratedDeutsche BankHold$380$400
Aug-05-26ReiteratedStifel Nicolaus$380$420
Aug-05-26ReiteratedEvercore ISI GroupOutperform$410$420
Aug-05-26ReiteratedRBC CapitalOutperform$435$475
Aug-05-26UpgradeTD CowenHoldBuy
Aug-05-26ReiteratedBarclaysOverweight$425$460
Jul-14-26ReiteratedGoldman SachsBuy$425
Jul-09-26ReiteratedMorgan StanleyEqual Weight$350$390
Jul-08-26InitiatedRBC CapitalOutperform$435
Latest News
Aug-09-26
Aug-09-2611:04AM
Aug-06-26
Aug-05-26
Aug-04-26
Jul-31-26
Jul-31-2609:49AM
Jul-29-26
Jul-28-26
Jul-27-26
Jul-24-26
Company

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,6443,1652,958
Cost of Goods Sold Incl. D&A2,2861,3371,200
Gross Profit2,3581,8291,758
Selling, General and Administrative Excl. Other1,210740690
Research and Development322195183
Other Operating Expense457059
Operating Income370893826
Interest Expense1397090
Unusual Expense
Non-Operating Income (Expense)-26-6918
Net Income Before Taxes205755755
Income Taxes39112117
Consolidated Net Income166643638
Net Income From Continuing Operations166643638
Net Income166643638
EPS (Recurring)4.0210.8010.75
EPS (Basic, Before Extraordinaries)4.0210.8010.75
EPS (Diluted)4.0110.7610.71
EBITDA8951,0121,036
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio102.5235.3034.64
Price To Sales Ratio7.207.40
Gross Margin50.7857.7959.43
Operating Margin7.9728.2127.92
Net Margin3.5720.3221.57
Shares Outstanding06059
Market Capitalization22,79021,888
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$432.76$388.95$345.13$301.31$257.50 Close Price0.00M0.36M0.72M1.08M1.44MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
KUEBLER CHRISTOPHER ADirectorAug 06 '26Option Exercise136.433,626494,69521,434Aug 07
KUEBLER CHRISTOPHER ADirectorAug 06 '26Sale397.943,6261,442,93017,808Aug 07
Jiang WeiDirectorMar 16 '26Buy289.46500144,7303,441Mar 18
FEARON RICHARD HDirectorMar 06 '26Buy306.341,000306,3403,302Mar 10
KUEBLER CHRISTOPHER ADirectorNov 05 '25Option Exercise130.353,761490,24618,796Nov 07
FEARON RICHARD HDirectorMay 28 '24Buy332.901,000332,9001,653May 29
KUEBLER CHRISTOPHER ADirectorMay 15 '24Option Exercise113.884,000455,52018,716May 16
KUEBLER CHRISTOPHER ADirectorMay 15 '24Sale361.644,0001,446,56014,716May 16
BADDOUR LINDADirectorMar 13 '24Sale355.54500177,7702,250Mar 14
KUEBLER CHRISTOPHER ADirectorAug 04 '23Option Exercise99.224,000396,88018,382Aug 07
KUEBLER CHRISTOPHER ADirectorAug 04 '23Sale291.484,0001,165,92014,382Aug 07
VERGNANO MARK PDirectorFeb 28 '23Buy313.323,185997,9273,557Mar 01
CONARD EDWARDDirectorNov 30 '22Option Exercise212.068,0001,696,50075,283Dec 08
CONARD EDWARDDirectorNov 30 '22Sale334.701,059354,44774,224Dec 08
KUEBLER CHRISTOPHER Adirector:May 19 '22Sale328.784,0001,315,12014,064May 23
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.